Lawrence Steinman, Director of Pasithea Therapeutics Corp. (Ticker: KTTA), on November 28, 2025, purchased 133,333 shares of common stock at a price of $0.75 per share. After the transaction, Mr. Steinman holds a total of 199,691 shares of common stock. The purchase by executives and directors is usually regarded as a sign of confidence in the company's prospects, which may positively impact the company's stock price.